Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Alper Kearney"'
Autor:
Zhifen Yang, Lingyu Li, Ahu Turkoz, Pohan Chen, Rona Harari-Steinfeld, Maggie Bobbin, Ofir Stefanson, Hana Choi, Violena Pietrobon, Bennett Alphson, Angshumala Goswami, Vitaly Balan, Alper Kearney, Dharmesh Patel, Jin Yang, Damla Inel, Veena Vinod, Alessandra Cesano, Bing Wang, Kyung-Ho Roh, Lei S. Qi, Francesco M. Marincola
Publikováno v:
Journal of Translational Medicine, Vol 19, Iss 1, Pp 1-18 (2021)
Abstract Background Adoptive transfer of chimeric antigen receptor (CAR)-engineered T cells combined with checkpoint inhibition may prevent T cell exhaustion and improve clinical outcomes. However, the approach is limited by cumulative costs and toxi
Externí odkaz:
https://doaj.org/article/fb0228a28866446a85e61c3402715418
Autor:
Francesco M. Marincola, Lingyu Li, Rona Harari-Steinfeld, Bing Wang, Lei S. Qi, Veena Vinod, Kyung-Ho Roh, Bennett Alphson, Damla Inel, Jin Yang, Alper Kearney, Zhifen Yang, Maggie Bobbin, Ofir Stefanson, Ahu Turkoz, Pohan Chen, Violena Pietrobon, Alessandra Cesano, Vitaly Balan, Dharmesh Patel, Hana Choi, Angshumala Goswami
Publikováno v:
Journal of Translational Medicine
Journal of Translational Medicine, Vol 19, Iss 1, Pp 1-18 (2021)
Journal of Translational Medicine, Vol 19, Iss 1, Pp 1-18 (2021)
Background Adoptive transfer of chimeric antigen receptor (CAR)-engineered T cells combined with checkpoint inhibition may prevent T cell exhaustion and improve clinical outcomes. However, the approach is limited by cumulative costs and toxicities. M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cb35d98bd5de0f0026e75553c9d9416
http://europepmc.org/articles/PMC8573881
http://europepmc.org/articles/PMC8573881
Autor:
Dharmeshkumar Patel, Angshumala Goswami, Vitaly Balan, Zhifen Yang, Lingyu Li, Sowndharya Rajavel, Alper Kearney, Rona Harari-Steinfeld, Maggie Bobbin, Bing Wang, Alessandra Cesano, Stanley Qi, Francesco Marincola
Publikováno v:
Regular and young investigator award abstracts.
Background The application of CRISPR-Cas9 for personalized medicine is potentially revolutionary for the treatment of several diseases including cancer. However, the bacterial origin of the Cas9 protein raises concerns about immunogenicity. Recent EL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::07ff09d8131808f752a82fa1aa422e0d
https://doi.org/10.1136/jitc-2020-sitc2020.0130
https://doi.org/10.1136/jitc-2020-sitc2020.0130
Autor:
Kyung-Ho Roh, Veena Vinod, Alper Kearney, Ofir Stefanson, Pohan Chen, Damla Inel, Zhifen Yang, Rona Harari-Steinfeld, Maggie Bobbin, Bing Wang, Francesco M. Marincola, Vitaly Balan, Ahu Turkoz, Alessandra Cesano, Lingyu Li, Dharmesh Patel, Hana Choi, Lei S. Qi
Publikováno v:
SSRN Electronic Journal.
Adoptive transfer of chimeric antigen receptor (CAR)-engineered T cells combined with checkpoint inhibition may prevent T cell exhaustion and improve clinical outcomes. However, the approach is limited by cumulative costs and toxicities. To overcome
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e7011816a007f106e025b895ad7bd390
https://doi.org/10.2139/ssrn.3656606
https://doi.org/10.2139/ssrn.3656606